SG11201900712SA - Memantine transdermal delivery systems - Google Patents

Memantine transdermal delivery systems

Info

Publication number
SG11201900712SA
SG11201900712SA SG11201900712SA SG11201900712SA SG11201900712SA SG 11201900712S A SG11201900712S A SG 11201900712SA SG 11201900712S A SG11201900712S A SG 11201900712SA SG 11201900712S A SG11201900712S A SG 11201900712SA SG 11201900712S A SG11201900712S A SG 11201900712SA
Authority
SG
Singapore
Prior art keywords
memantine
international
california
salt
transdermal delivery
Prior art date
Application number
SG11201900712SA
Inventor
Eun Soo Lee
Parminder Singh
Appala Sagi
Amit K Jain
Original Assignee
Corium Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corium Int Inc filed Critical Corium Int Inc
Publication of SG11201900712SA publication Critical patent/SG11201900712SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

140 160 0 20 40 60 8C 100 Time (hr) FIG. 2 ac 2 tlJ C C ro E (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 February 2018 (01.02.2018) WIP0 I PCT onion °nolo III 1101 °nom° 1 ois (10) International Publication Number WO 2018/022818 Al (51) International Patent Classification: A61K 31/13 (2006.01) A61P 25/28 (2006.01) A61K 9/70 (2006.01) A61P 9/10 (2006.01) A61P 25/00 (2006.01) (21) International Application Number: PCT/US2017/044051 (22) International Filing Date: 26 July 2017 (26.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/367,502 27 July 2016 (27.07.2016) US 62/423,133 16 November 2016 (16.11.2016) US 62/444,745 10 January 2017 (10.01.2017) US 62/444,763 10 January 2017 (10.01.2017) US 62/457,791 10 February 2017 (10.02.2017) US 62/457,794 10 February 2017 (10.02.2017) US 62/504,391 10 May 2017 (10.05.2017) US (71) Applicant: CORIUM INTERNATIONAL, INC. [US/US]; 235 Constitution Drive, Menlo Park, California 94025 (US). (72) Inventors: LEE, Eun Soo; 2575 Hampton Avenue, Red- wood City, California 94061 (US). SINGH, Parminder; 5504 Alvelais Drive, Union City, California 94587 (US). SAGI, Appala; 2025 California Street #42, Mountain View, California 94040 (US). JAIN, Amit K.; 825 Carino Terrace, Milpitas, California 95035 (US). (74) Agent: MOHR, Judy M. et al.; McDermott Will & Emery LLP, 500 North Capitol Street, NM., Washington, District of Columbia 20001-1531 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = (54) Title: MEMANTINE TRANSDERMAL DELIVERY SYSTEMS - Memantine salt, sodium bicarb -c - Memantine free base 40 —0-- Memantine salt, no sodium bicarb a) A Memantine salt, altemative to sodium bicarb (57) : Transdermal delivery systems for the systemic delivery of memantine are described, wherein the system comprises a drug reservoir layer and an adhesive layer, optionally together with one or more intermediate and/or supporting layers, wherein the drug reservoir layer comprises an acrylate polymer or copolymer, a permeation enhancer, a carrier, and memantine base generated in situ by reaction of a memantine salt and an alkaline salt. Compositions and kits comprising the various components, e.g., drug reservoir and/or adhesive compositions are described. Methods relating to treatment of CNS disorders, e.g., Alzheimer's disease and/or dementia, using the aforementioned transdermal delivery devices and/or compositions are also described. [Continued on next page] WO 2018/022818 Al IMEDIMOMMIDIRE10101011010HOHHOHOMEMNIE HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))
SG11201900712SA 2016-07-27 2017-07-26 Memantine transdermal delivery systems SG11201900712SA (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662367502P 2016-07-27 2016-07-27
US201662423133P 2016-11-16 2016-11-16
US201762444745P 2017-01-10 2017-01-10
US201762444763P 2017-01-10 2017-01-10
US201762457794P 2017-02-10 2017-02-10
US201762457791P 2017-02-10 2017-02-10
US201762504391P 2017-05-10 2017-05-10
PCT/US2017/044051 WO2018022818A1 (en) 2016-07-27 2017-07-26 Memantine transdermal delivery systems

Publications (1)

Publication Number Publication Date
SG11201900712SA true SG11201900712SA (en) 2019-02-27

Family

ID=59523315

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900712SA SG11201900712SA (en) 2016-07-27 2017-07-26 Memantine transdermal delivery systems

Country Status (11)

Country Link
US (1) US10945968B2 (en)
EP (1) EP3490544A1 (en)
JP (2) JP7071958B2 (en)
KR (1) KR102508993B1 (en)
CN (1) CN109789113A (en)
AU (1) AU2017301929B2 (en)
CA (1) CA3032103A1 (en)
MX (1) MX2019001104A (en)
RU (1) RU2764764C2 (en)
SG (1) SG11201900712SA (en)
WO (1) WO2018022818A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7174632B2 (en) 2016-06-23 2022-11-17 コリウム， インコーポレイテッド Adhesive matrix with hydrophilic and hydrophobic domains and therapeutic agents
EP3490544A1 (en) 2016-07-27 2019-06-05 Corium International, Inc. Memantine transdermal delivery systems
KR20230109782A (en) 2016-07-27 2023-07-20 코리움, 엘엘씨 Sodium bicarbonate in situ conversion driven transdermal delivery of amine drug
US20210212994A1 (en) * 2017-02-28 2021-07-15 Temple University-Of The Commonwealth System Of Higher Education Novel Econazole Nitrate Medical Patch and Methods of Use Thereof
US11173132B2 (en) 2017-12-20 2021-11-16 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
BR112021023509A2 (en) * 2019-07-09 2022-01-18 Lts Lohmann Therapie Systeme Ag A transdermal therapeutic system comprising an active agent-containing layer comprising an acrylic polymer and a skin contact layer comprising a silicone gel patch
CN115957200A (en) * 2023-02-23 2023-04-14 广州新济药业科技有限公司 Memantine transdermal patch and preparation method thereof

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
NL134681C (en) 1966-04-26
US3546141A (en) 1966-08-08 1970-12-08 Mc Donnell Douglas Corp Phosphorus-nitrogen polymers and process
CH603545A5 (en) 1972-04-20 1978-08-31 Merz & Co
DE2856393C2 (en) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Medicines used to treat Parkinson's disease
US4752478A (en) * 1984-12-17 1988-06-21 Merck & Co., Inc. Transdermal system for timolol
DE3572485D1 (en) 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
US4880633A (en) 1986-03-12 1989-11-14 Merck & Co., Inc. Transdermal drug delivery system
FI95572C (en) 1987-06-22 1996-02-26 Eisai Co Ltd Process for the preparation of a medicament useful as a piperidine derivative or its pharmaceutical salt
US4837027A (en) 1987-11-09 1989-06-06 Alza Corporation Transdermal drug delivery device
US4781924A (en) 1987-11-09 1988-11-01 Alza Corporation Transdermal drug delivery device
US4849224A (en) 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
US5026556A (en) 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
ES2059602T3 (en) 1989-04-14 1994-11-16 Merz & Co Gmbh & Co USE OF ADAMANTANE DERIVATIVES FOR THE PREVENTION AND TREATMENT OF BRAIN ISCHEMIA.
ATE107517T1 (en) * 1989-05-25 1994-07-15 Takeda Chemical Industries Ltd TRANSDERMAL THERAPEUTIC AGENT.
US5252588A (en) 1990-04-27 1993-10-12 Sekisui Kagaku Kogyo Kabushiki Kaisha Percutaneously absorbable crosslinked polyvinylpyrrolidone eperisone or tolperisone preparation
ATE111351T1 (en) 1990-07-23 1994-09-15 Alza Corp ORAL OSMOTIC DEVICE FOR THE DELIVERY OF NICOTIN.
IT1243745B (en) * 1990-10-17 1994-06-21 Vectorpharma Int TRANSDERMAL THERAPEUTIC COMPOSITIONS CONTAINING DRUG AND / OR PROMOTING AGENT OF THE SKIN ABSORPTION SUPPORTED ON MICROPOROUS PARTICLES AND POLYMERIC MICROSPHERES AND THEIR PREPARATION.
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5123900A (en) 1991-08-16 1992-06-23 Bertek, Inc. Moisture permeable double disk
JPH06199659A (en) 1992-10-28 1994-07-19 Hisamitsu Pharmaceut Co Inc Apparatus for percutaneous treatment
US5424077A (en) 1993-07-13 1995-06-13 Church & Dwight Co., Inc. Co-micronized bicarbonate salt compositions
PT781122E (en) 1994-09-14 2000-11-30 Minnesota Mining & Mfg MATRIX FOR TRANSDERMIC DISTRIBUTION OF DRUGS
US5635203A (en) 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
EP0799029A1 (en) 1994-12-21 1997-10-08 Theratech, Inc. Transdermal delivery system with adhesive overlay and peel seal disc
AU6032696A (en) 1995-06-07 1996-12-30 Cygnus Therapeutic Systems Pressure sensitive acrylate adhesive composition cross-linke d with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group
DE19531342B4 (en) 1995-08-25 2007-11-29 Merz Pharma Gmbh & Co. Kgaa Use of aminoadamantane compounds as immunoregulators
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US5958919A (en) 1996-09-20 1999-09-28 Washington University Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
US6004578A (en) 1996-10-24 1999-12-21 Alza Corporation Permeation enhances for transdermal drug delivery compositions, devices and methods
US5866585A (en) 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US6193993B1 (en) 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6562368B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
US20020192243A1 (en) 1999-12-16 2002-12-19 Tsung-Min Hsu Transdermal and topical administration of drugs for the treatment of Alzheimer's disease using basic enhancers
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
AU2002214364B2 (en) 2000-11-06 2004-08-19 Samyang Biopharmaceuticals Corporation Transdermal drug delivery system with improved water absorbability and adhesion properties
DE60233217D1 (en) 2001-05-01 2009-09-17 Corium Internat Inc HYDROGEL COMPOSITIONS
US7250394B2 (en) 2001-08-20 2007-07-31 Maiken Nedergaard Treatment of glial tumors with glutamate antagonists
BR0212311A (en) 2001-09-04 2004-10-13 Trommsdorff Arzneimittel Plaster for the treatment of nail disorders and disorders
US7273619B2 (en) 2002-01-17 2007-09-25 Samyang Corporation Transdermal composition of an antivomiting agent
KR100852834B1 (en) 2002-10-24 2008-08-18 메르츠 파마 게엠베하 운트 코. 카가아 A pharmaceutical product comprising 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors and combination therapy using these compounds
NZ546106A (en) 2003-10-10 2008-10-31 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
CA2540921A1 (en) 2003-10-22 2005-09-01 Merz Pharma Gmbh & Co. Kgaa The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic ass peptides in amyloidopathies
US20080026081A1 (en) 2003-11-21 2008-01-31 Axel Unterbeck Methods of Treatment Using (+)-Isopropyl 2-Ethoxyethyl-4-(2-Chloro-3-Cyano-Phenyl)-1,4-Dihydro-2,6-Dimethyl-Pyridine-3,5-Dicarboxylate
US7176185B2 (en) 2003-11-25 2007-02-13 Tsrl, Inc. Short peptide carrier system for cellular delivery of agent
KR20130006523A (en) 2004-02-17 2013-01-16 트랜스셉트 파마슈티칼스, 인코포레이티드 Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US7670838B2 (en) 2004-05-24 2010-03-02 The Board Of Trustees Of The Leland Stanford Junior University Coupling of excitation and neurogenesis in neural stem/progenitor cells
JPWO2005115355A1 (en) 2004-05-28 2008-03-27 久光製薬株式会社 Patch preparation
TW200616608A (en) 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US20060078604A1 (en) 2004-10-08 2006-04-13 Noven Pharmaceuticals, Inc. Transdermal drug delivery device including an occlusive backing
US7744918B2 (en) 2004-11-22 2010-06-29 Hisamitsu Pharmaceutical Co., Inc. Drug-containing patch
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
MX2007007301A (en) 2005-01-11 2008-02-11 Teva Pharm Fine Chemicals Srl Polymorphs of memantine hydrochloride.
JP5084496B2 (en) 2005-02-04 2012-11-28 久光製薬株式会社 Transdermal patch
DE602006016934D1 (en) 2005-04-06 2010-10-28 Adamas Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR TREATING CNS DISEASES
US7888422B2 (en) 2005-11-09 2011-02-15 Mylan Technologies Inc. Long-wearing removable pressure sensitive adhesive
US20100121290A1 (en) 2006-03-28 2010-05-13 Torben Rasmussen Multilayer Film
IL175338A0 (en) 2006-05-01 2006-09-05 Biota Ltd Orally administrable films and preparation thereof
KR20090009951A (en) 2006-05-08 2009-01-23 데이고꾸세이약꾸가부시끼가이샤 Transdermally absorbable preparation comprising antidementia agent
JP5097359B2 (en) 2006-05-09 2012-12-12 久光製薬株式会社 Donepezil transdermal preparation
WO2007132476A2 (en) * 2006-05-15 2007-11-22 Matrix Laboratories Limited A process for the preparation of memantine hydrochloride
US9248104B2 (en) 2006-08-17 2016-02-02 Core Tech Solutions, Inc. Transdermal methods and systems for treating Alzheimer's disease
US20080107719A1 (en) 2006-11-08 2008-05-08 Sukhon Likitlersuang Transdermal drug delivery system
EP2638906A1 (en) 2006-12-01 2013-09-18 Nitto Denko Corporation Stabilized adhesive preparation containing donepezil
JP5037523B2 (en) 2006-12-01 2012-09-26 日東電工株式会社 Method for suppressing coloration of donepezil-containing patch preparation, and method for reducing the amount of donepezil related substances produced
TW200838479A (en) 2006-12-01 2008-10-01 Nitto Denko Corp Percutaneously absorbable preparation
JP5403948B2 (en) * 2007-06-07 2014-01-29 久光製薬株式会社 Memantine-containing transdermal absorption preparation
GEP20125717B (en) 2007-07-10 2012-12-25 Agile Therapeutics Inc Device for medicine direct dermal delivery
JP2009203213A (en) 2008-02-28 2009-09-10 Kosumedei Seiyaku Kk Percutaneous absorption pharmaceutical composition
DE102008013701A1 (en) * 2008-03-11 2009-09-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system with stabilized membrane
KR101454362B1 (en) 2008-03-24 2014-10-23 아이큐어 주식회사 Percutaneous absorption preparations for the treatment of dementia containg donepezil as an active ingredient
US20090291127A1 (en) 2008-05-21 2009-11-26 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
PE20100371A1 (en) 2008-10-31 2010-06-01 Lexicon Pharmaceuticals Inc S1P RECEPTOR AGONISTS FOR THE TREATMENT OF CEREBRAL MALARIA
US20100178037A1 (en) 2009-01-12 2010-07-15 Te-Wei Chen Display apparatus, video generation apparatus, and method thereof
AU2010204986B2 (en) 2009-01-14 2016-06-02 Corium International, Inc. Transdermal administration of tamsulosin
TWI552773B (en) 2009-05-01 2016-10-11 久光製藥股份有限公司 Transdermal absorption preparation
CN102630160B (en) 2009-09-16 2014-05-07 株式会社三养生物制药 Transdermal delivery system, method for manufacturing the same, and transdermal delivery method using the system
KR101734602B1 (en) 2009-10-21 2017-05-11 데이고꾸세이약꾸가부시끼가이샤 Transdermally absorbable donepezil-containing preparation
CN102048678A (en) 2009-10-30 2011-05-11 北京隆旗生物科技有限公司 Transdermal absorption preparation of oxybutynin as well as preparation method and medication application thereof
GB0921481D0 (en) 2009-12-08 2010-01-20 Vectura Ltd Process and product
JP2012236773A (en) * 2009-12-16 2012-12-06 Goto Takeshi Transdermally absorbable preparation of anti-dementia drug
CA2785639A1 (en) 2009-12-30 2011-07-07 Novartis Ag Melt extruded nicotine thin strips
US20110244023A1 (en) 2010-03-30 2011-10-06 Phosphagenics Limited Transdermal delivery patch
EP2564848B1 (en) 2010-04-28 2015-09-02 Hisamitsu Pharmaceutical Co., Inc. Transdermally absorbable donepezil-containing preparation
WO2011146583A2 (en) 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet formulations
RU2578971C2 (en) * 2010-06-17 2016-03-27 Лтс Ломанн Терапи-Системе Аг Transdermal administration of memantine
DE102010024105A1 (en) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermal administration of memantine
US20140370076A1 (en) 2010-06-30 2014-12-18 Nal Pharmaceuticals, Ltd. Transdermal drug delivery system containing donepezil
WO2012051333A1 (en) * 2010-10-12 2012-04-19 The Johns Hopkins University Antitussive compositions comprising memantine
WO2012057212A1 (en) * 2010-10-28 2012-05-03 久光製薬株式会社 Percutaneous absorption type formulation
JP5699554B2 (en) 2010-11-11 2015-04-15 富士通株式会社 Vector processing circuit, instruction issue control method, and processor system
WO2012084969A1 (en) 2010-12-22 2012-06-28 Hexal Ag Adhesive composition containing rotigotine and transdermal therapeutic system comprising the adhesive composition
TWI433904B (en) 2011-01-12 2014-04-11 Taiwan Biotech Co Ltd Donepezil transdermal patch
US8673338B2 (en) 2011-07-29 2014-03-18 Massachusetts Eye And Ear Infirmary Methods of delivering pharmaceutical agents
JP5820207B2 (en) 2011-09-13 2015-11-24 日東電工株式会社 Transdermal absorption enhancing composition and patch preparation
KR101239150B1 (en) 2012-02-28 2013-03-06 에스케이케미칼주식회사 Donepezil-containing transdermal delivery system and process for preparing the same
US20140256690A1 (en) 2013-03-08 2014-09-11 Agile Therapeutics, Inc. Contraceptive method
WO2014174564A1 (en) 2013-04-22 2014-10-30 祐徳薬品工業株式会社 Adhesive patch drug formulation of transdermal absorption type containing memantine
JP5415645B1 (en) 2013-06-28 2014-02-12 久光製薬株式会社 Manufacturing method of patch, patch and package
RU2018105761A (en) 2013-10-07 2019-02-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. DEVICES FOR TRANSDERMAL DELIVERY OF DEXMEDETOMIDIDINE AND WAYS OF THEIR APPLICATION
EP3054933A4 (en) 2013-10-11 2017-03-15 Teikoku Pharma USA, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
KR101485822B1 (en) 2014-01-22 2015-01-23 주식회사 대웅제약 Transdermal drug delivery system comprising donepezil or its salt
JP2015151370A (en) 2014-02-14 2015-08-24 日東電工株式会社 patch preparation
CA2951706A1 (en) 2014-06-24 2015-12-30 KAT Transdermals LLC Transdermal delivery system
US10238648B2 (en) 2014-07-18 2019-03-26 Buzzz Pharmaceuticals Ltd. Abuse deterrent opioid/opioid-antagonist transdermal patch
CN106687138B (en) * 2014-09-03 2021-10-15 日东电工株式会社 Vaccine pharmaceutical composition for cellular immunization comprising bisphosphonate agent
WO2016046675A1 (en) 2014-09-28 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of neurological diseases
DK3235494T3 (en) 2014-12-18 2020-03-02 Icure Pharm Inc Transdermal preparation containing donepezil as active ingredient
CN115252586A (en) 2015-06-22 2022-11-01 考里安公司 Transdermal adhesive compositions containing poorly soluble therapeutic agents
KR102005201B1 (en) 2015-07-27 2019-07-29 히사미쓰 세이야꾸 가부시키가이샤 Method for manufacturing asenapine-containing patch
CN108697655B (en) * 2015-12-30 2021-12-10 考里安公司 Systems and methods for long-term transdermal administration
CN105693556A (en) 2016-03-01 2016-06-22 巴斯特医药科技（常州）有限公司 Transformation method for rivastigmine tartrate and patch prepared from product of rivastigmine tartrate
JP7174632B2 (en) 2016-06-23 2022-11-17 コリウム， インコーポレイテッド Adhesive matrix with hydrophilic and hydrophobic domains and therapeutic agents
KR20230109782A (en) 2016-07-27 2023-07-20 코리움, 엘엘씨 Sodium bicarbonate in situ conversion driven transdermal delivery of amine drug
EP3490559A1 (en) 2016-07-27 2019-06-05 Corium International, Inc. Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
EP3490544A1 (en) 2016-07-27 2019-06-05 Corium International, Inc. Memantine transdermal delivery systems
SG11202000415PA (en) 2017-07-26 2020-02-27 Corium Inc Transdermal delivery system with a microporous membrane having solvent-filled pores

Also Published As

Publication number Publication date
EP3490544A1 (en) 2019-06-05
KR102508993B1 (en) 2023-03-10
JP2022087276A (en) 2022-06-09
AU2017301929B2 (en) 2023-03-02
RU2019105280A3 (en) 2020-12-03
JP2019522025A (en) 2019-08-08
WO2018022818A1 (en) 2018-02-01
CN109789113A (en) 2019-05-21
KR20190032551A (en) 2019-03-27
CA3032103A1 (en) 2018-02-01
US10945968B2 (en) 2021-03-16
AU2017301929A1 (en) 2019-02-14
US20180028466A1 (en) 2018-02-01
RU2019105280A (en) 2020-08-27
JP7071958B2 (en) 2022-05-19
RU2764764C2 (en) 2022-01-21
MX2019001104A (en) 2019-10-02

Similar Documents

Publication Publication Date Title
SG11201900712SA (en) Memantine transdermal delivery systems
SG11201900692WA (en) Donepezil transdermal delivery system
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201901445TA (en) A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
SG11201908012SA (en) Cyclic sulfamide compounds and methods of using same
SG11201908075UA (en) A microneedle device
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201901006RA (en) Systems and methods for enhanced organizational transparency using a credit chain
SG11201811150WA (en) Ev-mediated delivery of binding protein-small molecule conjugates
SG11201408186TA (en) Pyridinone and pyridazinone derivatives
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201807421TA (en) The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
SG11201804312RA (en) Microbubble-chemotherapeutic agent complex for sonodynamic therapy
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201908743SA (en) Methods and compositions for modulation of immune cells
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201909083UA (en) Piperidines as covalent menin inhibitors
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201804721SA (en) Modulators of complement activity
SG11201809561WA (en) 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (uti) treatment
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders